VistaGen Therapeutics (NASDAQ:VTGN) Cut to “Hold” at Stifel Nicolaus

VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by investment analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday,Finviz reports. They presently have a $1.00 target price on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 25.47% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, October 8th. William Blair reiterated an “outperform” rating on shares of VistaGen Therapeutics in a research report on Tuesday, October 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $1.00.

VistaGen Therapeutics Stock Performance

VTGN traded down $3.56 on Wednesday, hitting $0.80. The company had a trading volume of 31,639,389 shares, compared to its average volume of 493,772. The stock has a market capitalization of $31.47 million, a price-to-earnings ratio of -0.42 and a beta of 0.56. The stock has a fifty day moving average price of $4.20 and a 200-day moving average price of $3.32. VistaGen Therapeutics has a 12-month low of $0.75 and a 12-month high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.16 million. Analysts forecast that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stempoint Capital LP boosted its stake in shares of VistaGen Therapeutics by 2.0% during the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock worth $4,827,000 after acquiring an additional 46,700 shares in the last quarter. ADAR1 Capital Management LLC raised its holdings in VistaGen Therapeutics by 246.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock worth $1,052,000 after purchasing an additional 299,304 shares during the period. Two Sigma Investments LP grew its holdings in VistaGen Therapeutics by 223.5% in the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after purchasing an additional 199,958 shares during the period. AdvisorShares Investments LLC increased its position in shares of VistaGen Therapeutics by 1.9% in the third quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock valued at $735,000 after buying an additional 3,884 shares in the last quarter. Finally, Boothbay Fund Management LLC raised its stake in shares of VistaGen Therapeutics by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after buying an additional 19,166 shares during the period. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.